[1] GUINEA J, HAGEN F, PELAEZ T, et al. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain[J]. Med Mycol,2010,48(7):942-948. [2] MAZIARZ E K, PERFECT J R. Cryptococcosis[J]. Infect Dis Clin North Am,2016,30(1):179-206. [3] VPARK B J, WANNEMUEHLER K A, MARSTON B J, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. Aids,2009,23(4):525-530. [4] SELB R, FUCHS V, GRAF B, et al. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017[J]. Int J Med Microbiol,2019,309(6):151336. [5] GUTCH R S, NAWANGE S R, SINGH S M, et al. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India[J]. Braz J Microbiol,2015,46(4):1125-1133. [6] ELLIS D H, PFEIFFER T J. Natural habitat of Cryptococcus neoformans var. gattii[J]. J Clin Microbiol,1990,28(7):1642-1644. [7] SPEED B, DUNT D. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans[J]. Clin Infect Dis,1995,21(1):28-36. [8] FANG W, FA Z, LIAO W. Epidemiology of Cryptococcus and cryptococcosis in China[J]. Fungal Genet Biol,2015,78:7-15.DOI:10.1016/j.fgb.2014.10.017. [9] CHEN Y H, YU F, BIAN Z Y, et al. Multilocus sequence typing reveals both shared and unique genotypes of Cryptococcus neoformans in Jiangxi Province, China[J]. Sci Rep,2018,8(1):1495. [10] FENG X, YAO Z, REN D, et al. Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients[J]. FEMS Yeast Res, 2008,8(6):930-938. [11] WU S Y, KANG M, LIU Y, et al. Molecular epidemiology and antifungal susceptibilities of Cryptococcus species isolates from HIV and non-HIV patients in Southwest China[J]. Eur J Clin Microbiol Infect Dis,2021,40(2):287-295. [12] JIN L, CAO J R, XUE X Y, et al. Clinical and microbiological characteristics of Cryptococcus gattii isolated from 7 hospitals in China[J]. BMC Microbiol,2020,20(1):73. [13] KLEIN K R, HALL L, DEML S M, et al. Identification of Cryptococcus gattii by use of L-canavanine glycine bromothymol blue medium and DNA sequencing[J]. J Clin Microbiol,2009,47(11):3669-3672. [14] MCTAGGART L R, LEI E, RICHARDSON S E, et al. Rapid identification of Cryptococcus neoformans and Cryptococcus gattii by matrix-assisted laser desorption ionization-time of flight mass spectrometry[J]. J Clin Microbiol,2011,49(8):3050-3053. [15] FAVALESSA O C, de PAULA D A, DUTRA V, et al. Molecular typing and in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil[J]. J Infect Dev Ctries. 2014,8(8):1037-1043. [16] PFALLER M A, MESSER S A, BOYKEN L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans(1990 to 2004)[J]. J Clin Microbiol,2005,43(5):2163-2167. [17] DIAS A L T, MATSUMOTO F E, MELHEM M S C, et al. Comparative analysis of Etest and broth microdilution method (AFST-EUCAST) for trends in antifungal drug susceptibility testing of Brazilian Cryptococcus neoformans isolates[J]. J Med Microbiol,2006,55(Pt 12):1693-1699. [18] REVANKAR S G, KIRKPATRICK W R, MCATEE R K, et al. Interpretation of trailing endpoints in antifungal susceptibility testing by the National Committee for Clinical Laboratory Standards method[J]. J Clin Microbiol, 1998,36(1):153-156. [19] RODRIGUEZ-TUDELA J L, MARTINEZ-SUAREZ J V, DRONDA F, et al. Correlation of in-vitro susceptibility test results with clinical response:a study of azole therapy in AIDS patients[J]. J Antimicrob Chemother,1995,35(6):793-804. [20] ESPINEL-INGROFF A, CHOWDHARY A, CUENCA-ESTRELLA M, et al. Cryptococcus neoformans-Cryptococcus gattii species complex:an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine[J].Antimicrob Agents Chemother,2012,56(6):3107-3113. [21] ESPINEL-INGROFF A, ALLER A I, CANTON E, et al. Cryptococcus neoformans-Cryptococcus gattii species complex:an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole[J]. Antimicrob Agents Chemother,2012,56(11):5898-5906. [22] ESPINEL-INGROFF A, CHOWDHARY A, GONZALEZ G M, et al. Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method[J]. Antimicrob Agents Chemother,2015,59(1):666-668. [23] HUANG C, TSUI C K M, ChEN M, et al. Emerging Cryptococcus gattii species complex infections in Guangxi, southern China[J]. PLoS Negl Trop Dis,2020,14(8):e0008493. [24] ChEN J, VARMA A, DIAZ M R, et al. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China[J]. Emerg Infect Dis, 2008,14(5):755-762. [25] WU S Y, LEI Y, KANG M, et al. Molecular characterisation of clinical Cryptococcus neoformans and Cryptococcus gattii isolates from Sichuan province, China[J]. Mycoses,2015,58(5):280-287. [26] DROMER F, MATHOULIN S, DUPONT B, et al. Epidemiology of cryptococcosis in France:a 9-year survey (1985-1993). French Cryptococcosis Study Group[J]. Clin Infect Dis, 1996,23(1):82-90. [27] MOOSA M Y, COOVADIA Y M. Cryptococcal meningitis in Durban, South Africa:a comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients[J]. Clin Infect Dis,1997,24(2):131-134. [28] SINGHAL N, KUMAR M, KANAUJIA P K, et al. MALDI-TOF mass spectrometry:an emerging technology for microbial identification and diagnosis[J]. Front Microbiol,2015,6:791.DOI:10.3389/fmicb.2015.00791. [29] FIRACATIVE C, TRILLES L, MEYER W. MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex[J]. PLoS One,2012,7(5):e37566. [30] CHENG K, CHUI H, DOMISH L, et al. Recent development of mass spectrometry and proteomics applications in identification and typing of bacteria[J]. Proteomics Clin Appl,2016,10(4):346-357. [31] PERKINS A, GOMEZ L A, MELLADO E, et al. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans[J]. J Antimicrob Chemother,2005,56(6):1144-1147. [32] LIA M, CARETTE A, TANG H, et al. Functional dissection of the chromosome 13q14 tumor-suppressor locus using transgenic mouse lines[J]. Blood,2012,119(13):2981-2990. [33] SAR B, MONCHY D, Vann M, et al. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates:April 2000 to March 2002[J]. J Antimicrob Chemother, 2004,54(2):563-565. [34] HERKERT P F, MEIS J F, LUCCA O S G, et al. Molecular characterization and antifungal susceptibility testing of Cryptococcus neoformans sensu stricto from southern Brazil[J]. J Med Microbiol,2018,67(4):560-569. [35] ARSIC A V, PEKMEZOVIC M G, MEIS J F, et al. Molecular epidemiology and antifungal susceptibility of Serbian Cryptococcus neoformans isolates[J]. Mycoses, 2014,57(6):380-387. [36] THOMPSON G R 3rd, WIEDERHOLD N P, FOTHERGILL A W, et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans[J]. Antimicrob Agents Chemother,2009,53(1):309-311. |